[{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $2 Million Research Milestone in Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"ProQR Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ProQR to Present its Axiomer RNA Editing Technology at the Oligonucleotide and Peptide Therapeutics Conference (TIDES USA) 2022","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"ProQR Therapeutics"},{"orgOrder":0,"company":"Zerion Pharma","sponsor":"Hovione","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zerion Pharma and Hovione Extend Partnership to Cover Use of The Dispersome\u00ae Technology Platform in Nutraceuticals","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Zerion Pharma"},{"orgOrder":0,"company":"Synaffix","sponsor":"Emergence Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$360.0 million","newsHeadline":"Emergence Therapeutics Licenses Synaffix ADC Technology Platform in $360M Deal","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"OliPass","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Vanda Pharmaceuticals"},{"orgOrder":0,"company":"Nimble Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Nimble Therapeutics"},{"orgOrder":0,"company":"IntoCell","sponsor":"ADC Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IntoCell Enters into Development and License Option Agreement with ADC Therapeutics","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"IntoCell"},{"orgOrder":0,"company":"Synaffix","sponsor":"Hummingbird Bioscience","pharmaFlowCategory":"D","amount":"$150.0 million","upfrontCash":"Undisclosed","newsHeadline":"Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"NETHERLANDS","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Synaffix"},{"orgOrder":0,"company":"Chroma Medicine","sponsor":"Google Ventures","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Chroma Medicine Secures $135M in Series B Financing to Advance Breakthrough Epigenetic Editing Technology and Expand Pipeline of Durable Precision Genomic Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Chroma Medicine"},{"orgOrder":0,"company":"Ring Therapeutics","sponsor":"Alexandria Venture Investments","pharmaFlowCategory":"D","amount":"$86.5 million","upfrontCash":"Undisclosed","newsHeadline":"Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Ring Therapeutics"},{"orgOrder":0,"company":"Xeris Pharmaceuticals","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect\u2122","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Xeris Pharmaceuticals"},{"orgOrder":0,"company":"Matinas BioPharma","sponsor":"BioNTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioNTech and Matinas End Oral mRNA Delivery Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Vaccine","graph2":"Matinas BioPharma"},{"orgOrder":0,"company":"Silence Therapeutics","sponsor":"Hansoh Pharma","pharmaFlowCategory":"D","amount":"$1,316.0 million","upfrontCash":"$16.0 million","newsHeadline":"Silence Therapeutics Achieves $4 Million in Research Milestone Payments from Hansoh Pharma Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Silence Therapeutics"},{"orgOrder":0,"company":"Shape Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Shape Therapeutics"},{"orgOrder":0,"company":"MedinCell","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$1,935.0 million","upfrontCash":"$35.0 million","newsHeadline":"Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies","therapeuticArea":"Technology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Undisclosed","graph2":"MedinCell"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Under the agreement, Medincell and AbbVie will co-develop, and AbbVie will commercialize up to six cutting-edge long-acting injectables (LAI). Medincell will use its commercial-stage long-acting injectable technology platform to formulate innovative therapies.
Under the collaboration, ShapeTX will use its proprietary AI-powered RNA editing platform to develop a potential one-time therapy for patients with high unmet needs for an undisclosed disease affecting millions of people worldwide.
The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.
The termination is based on the results of an initial in vivo study of an oral mRNA delivery formulation, developed using BioNTech’s mRNA vaccine development expertise and Matinas’ LNC Delivery Platform Technology, which did not demonstrated oral preclinical activity.
Under the terms of the agreement, Xeris will use its proprietary drug-formulation platform, XeriJect™, to develop ultra-highly concentrated, ready-to-use, small volume subcutaneous injections of two undisclosed monoclonal antibodies (mAbs) developed by Regeneron.
The proceeds from the raise will advance Anellogy™ platform toward the clinic, transforming commensal anelloviruses into life-saving therapies, creating next-generation programable genetic medicines.
The funding will be used to progress chroma’s single-dose epigenetic editing therapies and support expansion of novel genetic medicine platform designed to enable precise gene regulation while preserving genomic integrity.
ADC Therapeutics' CD19-specific Antibody Drug Conjugate (ADC), Zynlonta (loncastuximab tesirine-lpyl) is FDA-approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies.
Under the terms of the agreement, Hummingbird Bio is granted rights to utilize Synaffix proprietary Antibody-Drug Conjugate (ADC) technologies GlycoConnect™ and HydraSpace™, in combination with select toxSYN™ linker-payloads.
Lead Product(s):
Antibody-drug Conjugate-based Therapy
Nimble has delivered lead compounds for four programs to its partners. This progress, across multiple targets and partners, validates the power of Nimble’s platform to optimize peptide therapeutics at unprecedented speed.